NO20066049L - Substituerte tiazoleddiksyrer som CRTH2-ligandere - Google Patents

Substituerte tiazoleddiksyrer som CRTH2-ligandere

Info

Publication number
NO20066049L
NO20066049L NO20066049A NO20066049A NO20066049L NO 20066049 L NO20066049 L NO 20066049L NO 20066049 A NO20066049 A NO 20066049A NO 20066049 A NO20066049 A NO 20066049A NO 20066049 L NO20066049 L NO 20066049L
Authority
NO
Norway
Prior art keywords
ring
membered
acetic acids
optionally substituted
substituted thiazole
Prior art date
Application number
NO20066049A
Other languages
English (en)
Inventor
Trond Ulven
Thomas Frimurer
Oystein Rist
Evi Kostenis
Thomas Hogberg
Jean-Marie Receveur
Marie Grimstrup
Original Assignee
7Tm Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412198A external-priority patent/GB0412198D0/en
Priority claimed from GB0414194A external-priority patent/GB0414194D0/en
Priority claimed from GB0424016A external-priority patent/GB0424016D0/en
Application filed by 7Tm Pharma As filed Critical 7Tm Pharma As
Publication of NO20066049L publication Critical patent/NO20066049L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med formel (I) er anvendbare til behandlingen av sykdom som gir respons på modulering av CRTH2-reseptoraktivitet, slik som astma, rhinitt, allergisk luftveis-syndrom og allergisk rhinobronkitt, hvor Xi er -S-, -0-, -N=N-, -NR7-, -CR7=CR8-, -CR7=N-, hvor R7 og R8 uavhengig av hverandre er hydrogen eller Ci-C3~alkyl; A er en karboksyl-gruppe -COOH eller en karboksylbioiso-ster; ringene Ar2 og Ar3 er uavhengig av hverandre en fenyl- eller 5- eller 6-leddet, monosyklisk heteroarylring, eller et bisyklisk ringsystem bestående av en 5- eller 6-leddet, karbosyklisk eller heterosyklisk ring som er benz-kondensert eller kondensert til en 5-eller 6-leddet, monosyklisk heteroarylring, hvor ringen eller ringsystemet eventuelt er substituert; ring B er som definert for Ar2 og Ar3, eller er en eventuelt substituert N-pyrrolidinyl-, N-piperidinyl- eller N-azepinylring; s er 0 eller 1; Li, L2 og L4 er linker-radikaler, som definert i beskrivelsen; og Qi og Q2 er substituenter, som definert i beskrivelsen.
NO20066049A 2004-05-29 2006-12-28 Substituerte tiazoleddiksyrer som CRTH2-ligandere NO20066049L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0412198A GB0412198D0 (en) 2004-05-29 2004-05-29 Medicinal use of receptor ligands
GB0414194A GB0414194D0 (en) 2004-06-24 2004-06-24 Medicinal use of receptor ligands
GB0424016A GB0424016D0 (en) 2004-10-29 2004-10-29 Medicinal use of receptor ligands
PCT/EP2005/005882 WO2005116001A1 (en) 2004-05-29 2005-05-30 Substituted thiazoleacetic as crth2 ligands

Publications (1)

Publication Number Publication Date
NO20066049L true NO20066049L (no) 2007-02-27

Family

ID=34968996

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066049A NO20066049L (no) 2004-05-29 2006-12-28 Substituerte tiazoleddiksyrer som CRTH2-ligandere

Country Status (13)

Country Link
US (1) US20080119456A1 (no)
EP (1) EP1758874A1 (no)
JP (1) JP2008503447A (no)
KR (1) KR20070044404A (no)
AU (1) AU2005247610A1 (no)
BR (1) BRPI0511671A (no)
CA (1) CA2568742A1 (no)
CR (1) CR8837A (no)
EA (1) EA200602288A1 (no)
IL (1) IL179693A0 (no)
MX (1) MXPA06013924A (no)
NO (1) NO20066049L (no)
WO (1) WO2005116001A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427381D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009105214A2 (en) 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
EP2351743A4 (en) * 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC CONNECTION
AR075153A1 (es) * 2009-01-30 2011-03-16 Glaxosmithkline Llc Compuesto hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil)-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2- tiofenocarboxamida en forma cristalina, composicion farmaceitica que lo comprende, procedimiento para prepararla, su uso para preparar un medicamento util para tratar o disminuir la
EA201200855A1 (ru) 2009-12-23 2013-04-30 Айронвуд Фармасьютикелз, Инк. Модуляторы crth2
US8987319B2 (en) 2010-02-04 2015-03-24 Radius Health, Inc. Selective androgen receptor modulators
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK183999A3 (en) * 1997-07-10 2000-08-14 Janssen Pharmaceutica Nv Il-5 inhibiting 6-azauracil derivatives
EP1045846B1 (en) * 1997-11-28 2003-05-02 Lg Chemical Limited Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
EP0987265A1 (en) * 1998-09-18 2000-03-22 Janssen Pharmaceutica N.V. Interleukin-5 inhibiting 6-azauracil derivatives
ATE318811T1 (de) * 1999-08-06 2006-03-15 Janssen Pharmaceutica Nv Interleukin-5 hemmende 6-azauracil derivate
US7276526B2 (en) * 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
WO2005116001A1 (en) 2005-12-08
KR20070044404A (ko) 2007-04-27
US20080119456A1 (en) 2008-05-22
BRPI0511671A (pt) 2008-01-02
JP2008503447A (ja) 2008-02-07
AU2005247610A1 (en) 2005-12-08
CA2568742A1 (en) 2005-12-08
IL179693A0 (en) 2007-05-15
EA200602288A1 (ru) 2007-10-26
EP1758874A1 (en) 2007-03-07
CR8837A (es) 2008-03-18
MXPA06013924A (es) 2007-07-18

Similar Documents

Publication Publication Date Title
NO20066049L (no) Substituerte tiazoleddiksyrer som CRTH2-ligandere
NO20066048L (no) CRTH2-reseptorligandere for medisinske anvendelser
NO20050014L (no) 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander
ATE538099T1 (de) 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
NO20050007L (no) 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander
ATE388147T1 (de) Thiazolderivate als a2b-antagonisten
EA201290260A1 (ru) Бензимидазол-имидазольные производные
EA200801494A1 (ru) Производные оксадиазола с активностью crth2 рецептора
ME01029B (me) VIŠESUPTITUISANI DERIVATI 2-ARIL-6-FENIL-IMIDAZO [1, 2α] PIRIDINI, NJIHOVO DOBIJANJE I NJIHOVA UPOTREBA U TERAPIJI
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
EA201070896A1 (ru) ЗАМЕЩЕННЫЕ АРИЛАМИДДИАЗЕПИНОПИРИМИДОНОВЫЕ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ АНОМАЛЬНОЙ АКТИВНОСТЬЮ GSK3β
ATE480239T1 (de) Angiogeneseinhibitoren
DE602007005811D1 (de) 6-substituierte isochinolinderivate als rock-1-inhibitoren
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
NO20063452L (no) Benzamid-derivater og deres anvendelse som glukokinaseaktiversingsmidler
RS54708B1 (en) ARYLETINYL DERIVATIVES
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
NO20075384L (no) Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer.
CY1112679T1 (el) Κινολινες και θεραπευτικη χρηση αυτων
WO2008136444A1 (ja) 縮合複素環誘導体
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
ATE469128T1 (de) Indole, die sich zur behandlung von mit dem androgenrezeptor in zusammenhang stehenden krankheiten eignen
MX2009012383A (es) Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas.
UY33149A (es) Compuestos carboxamida y su uso como inhibidores iv de calpaina
PE20070827A1 (es) DERIVADOS DE ISOQUINOLINA Y BENZO[h]ISOQUINOLINA, SU PREPARACION Y SU UTILIZACION EN TERAPEUTICA

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application